[Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Beta-2-Microglobulin (b2m) and or Ca-125 levels were measured in 367 serum samples of 66 ovarian cancer patients. CA-125 was found to be a suitable tool, even in single use, to monitorise the clinical course of the disease with acceptable sensitivity (o. 89) and specificity (o. 94). B2m showed a sensitivity of the same level (o. 87) the specificity of it however proved to be low (o. 48). In consequence of its low specificity the b2m as a single marker is not applicable in ovarian cancer. However, the addition of b2m to CA-125 resulted in higher specificity and sensitivity, as b2m probably has a different spectrum and yielded correct results at that points of the follow-up where CA-125 produced pseudo-positive or pseudo-negative results. The combination of b2m and CA-125 tumormarkers seems to be a suitable tool for follow-up ovarian cancer patients under and after treatment.
Hernádi
Z
Z
Universitäts-Frauenklinik der Medizinischen Universität Debrecen.
Molnár
V
V
Juhász
B
B
Pólka
R
R
Margitai
B
B
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D012086:Reoperation; D001613:beta 2-Microglobulin / Q000378:metabolism*
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D001613:beta 2-Microglobulin
Der prädiktive Wert der Tumormarkerkombination CA-125 und Beta-2-Mikroglobulin bei Ovarialkarzinom.